Phase 2 Study to Evaluate Efficacy and Safety of CS-3150 in Patients with Essential Hypertension

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221876

Enrollment

150

Registered

2012-08-07

Start date

2012-08-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

investigational material(s) Generic name etc : CS-3150 INN of investigational material : Esaxerenone Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Main Inclusion Criteria; - Sitting blood pressure:stable, mean systolic BP>=140 and =90 and - 130 mmHg, and diastolic BP >-80 mm Hg.

Exclusion criteria

Exclusion criteria: 1) Secondary hypertension or malignant hypertension 2) Subjects with diabetes or with treatment for diabetes 3) Serum potassium level = 5.1 mEq/L 4) Reversed day-night life cycle including overnight workers 5) eGFR < 60 mL/min/1.73 m^2

Design outcomes

Primary

Measure	Time frame
safety efficacy Change from baseline in sitting systolic and diastolic blood pressure Adverse events	—

Secondary

Measure	Time frame
efficacy Change from baseline in 24-hr blood pressure (ABPM)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026